{"i": ["LABAs", "tiotropium", "mizolastin", "aclidinium", "short - acting \u03b22 - agonists other than rescue medication", "long - acting anticholinergics", "muscarinic antagonists ( LAMAs )", "Ketotifen", "xanthines", "parenteral or oral corticosteroids", "NVA237", "OD dosing", "LAMA", "non - selective beta - blockers", "placebo -", "cromoglycate", "short - acting anticholinergics", "salbutamol / albuterol", "placebo", "intramuscular depot corticosteroids", "OD", "ipratropium bromide", "glycopyrronium bromide", "Glycopyrronium bromide", "glycopyrronium bromide .", "inactivated influenza vaccination , pneumococcal vaccination or any other inactivated vaccine", "Placebo", "inhaled corticosteroids ( ICS ) and long - acting \u03b22 - agonists ( LABA )", "BID dosing", "fixed combinations of inhaled short - acting anticholinergics and short - acting \u03b22 - agonists", "Glycopyrronium bromide ( NVA237 )", "systemic anticholinergics", "leukotriene antagonists", "Nedocromil"], "o": ["AEs", "safety and tolerability profile", "normalized FEV1", "forced expiratory volume in 1 second ( FEV1", "St . George ' s Respiratory Questionnaire ( SGRQ ) and Transition Dyspnoea Index", "bronchodilator FEV1 to forced vital capacity ( FVC ) ratio", "COPD worsening .", "healthcare utilization costs", "haematology or clinical chemistry parameter values", "pulse rate", "ECG parameters", "BID \u2013 OD difference in trough response", "safe and well tolerated", "efficacy and safety", "OD profiles", "FEV1 AUC0 - 12h", "night - time symptoms", "trough FEV1", "exercise tolerance and health status", "spirometric outcomes", "FEV1 response", "Haematology , blood chemistry and urinalysis parameters", "disease progression", "Pharmacodynamic steady - state", "adverse events ( AEs", "COPD worsening", "overall safety profile", "tolerability profiles", "Cardiac disorder", "FEV1 AUC0", "mean trough FEV1", "systolic pressure", "FEV1 and FVC", "bronchodilation and responder rates", "QTc interval", "COPD ( worsening )", "FEV1 AUC0 - 4h", "FEV 1", "nasopharyngitis and headache", "peak FEV1", "mild headache", "dose response", "bronchodilatory efficacy and duration of action", "duration of COPD", "Mean post - bronchodilator FEV1", "FEV1 AUC12 - 24h", "serious AEs", "death", "day - time symptoms", "vital signs", "duration of action , rapid onset of action", "bronchodilation", "FEV1 area under the curve", "pregnancies , assessing vital signs , and electrocardiogram ( ECG )", "nasopharyngitis", "airway calibre", "diastolic blood pressure", "dyspnoea , SGRQ and rescue medication use", "patient adherence", "FEV1 AUC0 - 4h , FEV1 AUC0 - 12h , and FEV1 AUC12 - 24h", "AUC0 - 24h FEV1", "spirometric profiles", "FEV1", "FEV1 AUC0 - 4h , FEV1 AUC0 - 12h , FEV1 AUC12 - 24h , FEV1", "tolerated", "AE frequency", "mean minimum and maximum values", "mortality risk", "dyspnoea and diarrhoea", "moderate / severe exacerbations", "adherence"]}